In October 2024, the Duke Clinical Research Institute (DCRI) convened a multidisciplinary think tank titled “Anti-Obesity Pharmacotherapy: Need for Guidance, Access, and Equity.” Emerging from this meeting, CVC faculty member and recent DCRI fellow Dr. Pishoy Gouda, along with his co-authors, published a report in JACC:Advances identifying actionable steps to advance the field of obesity medications.
To translate recent pharmaceutical innovation into population-wide health outcomes, the report outlines four essential action items:
- A Unified Research Roadmap: A cross-stakeholder strategy to align research efforts around an evidence-based framework. Priorities include refining obesity definitions and clinical outcomes, evaluating the role of medications across different disease stages, mapping pathophysiology (underlying biological processes), and improving health literacy among providers and the public.
- Standardized Metrics and Endpoints: To move beyond the limitations of body mass index (BMI) and better address the disease’s complexity, stakeholders advocate for metrics encompassing dysfunctional adiposity (harmful fat tissue), clinical symptoms, and obesity-related complications.
- Equitable Access: The report calls for a systematic evaluation of access barriers using population-wide data. This includes targeted strategies to address prohibitive costs and supply chain inconsistencies that fuel health disparities.
- Regulatory and Payer Framework: A new framework is needed to account for rapidly evolving evidence. By establishing a multi-stakeholder forum, regulators and payers can better align decision-making to ensure sustainable, long-term coverage.
Ultimately, while novel medications offer transformative potential, their impact depends on navigating these systemic hurdles. Prioritizing collaborative research is vital to ensure that scientific innovation translates into meaningful health outcomes for all.
